Recent Advances in Drug Therapy for Malaria
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 1542
Special Issue Editors
Interests: malaria; infection; plasmodium; immunology; parasitology; tropical diseases
Special Issue Information
Dear Colleagues,
Despite significant efforts, malaria continues to be a major health problem in sub-Saharan Africa and claims hundreds of thousands of victims yearly, mainly children under the age of five. Artemisinin combination therapy has been the cornerstone of antimalarial therapy in the last two decades, but the emergence of artemisinin resistance in P. falciparum poses a challenge for continuing to reduce malaria incidence and mortality globally. The first malaria vaccine has been recommended by the WHO since October 2021 for children aged five months and older living in areas with moderate to high malaria transmission. However, the vaccine has only shown modest efficacy; therefore, new therapeutic strategies remain essential to avoid malaria deaths in the coming years. In addition, drugs with preventive and transmission-blocking effects are crucial to take the next step towards eliminating malaria.
We are pleased to invite you to contribute with an article to this Special Issue on “Recent Advances in Drug Therapy for Malaria” to update the current state of the art and address ongoing knowledge gaps in malaria therapy.
This Special Issue aims to publish original research and review articles related to the prevention, treatment, and transmission blocking of malaria to assemble a collection of publications highlighting recent advances in drug therapy for malaria and to raise awareness of this life-threatening disease.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Antimalarial drug resistance;
- Malaria chemoprophylaxis;
- Drug therapy;
- Malaria elimination;
- Novel antimalarials;
- Plasmodium falciparum;
- Transmission blocking activity;
- Pharmacogenetics;
- Pharmacogenomics;
- Antimalarial drug design;
- Drug targeting;
- Antimalarial drug delivery.
I look forward to receiving your contributions.
Dr. Jana Held
Prof. Dr. Steffen Borrmann
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel antimalarials
- malaria elimination
- Plasmodium falciparum
- antimalarial drug resistance
- transmission blocking
- drug therapy
- artemisinin
- pharmacogenomics
- pharmacogenetics
